The Current Ratio as of July 2024 (TTM) for Exelixis, Inc. (EXEL) is 3.46

According to Exelixis, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 3.46. This represents a change of -9.54% compared to the average of 3.83 of the last 4 quarters.

Exelixis, Inc. (EXEL) Historical Current Ratio (quarterly & annually)

How has EXEL Current Ratio performed in the past?

The mean historical Current Ratio of Exelixis, Inc. over the last ten years is 4.68. The current 3.46 Current Ratio has changed 7.31% with respect to the historical average. Over the past ten years (40 quarters), EXEL's Current Ratio was at its highest in in the July 2020 quarter at 9.77. The Current Ratio was at its lowest in in the December 2014 quarter at 0.97.

Exelixis, Inc. (EXEL) Current Ratio by Quarter and Year

Discovering the peaks and valleys of Exelixis, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Exelixis, Inc. (EXEL) Average Current Ratio

How has EXEL Current Ratio performed in the past?

The current Current Ratio of Exelixis, Inc. (EXEL) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

Exelixis, Inc. (EXEL) Current Ratio vs. Peers

How is EXEL’s Current Ratio compared to its peers?

Exelixis, Inc.’s Current Ratio is less than TG Therapeutics, Inc. (3.62), less than Viking Therapeutics, Inc. (37.69), less than Madrigal Pharmaceuticals, Inc. (9.39), greater than BioXcel Therapeutics, Inc. (2.57), greater than BioMarin Pharmaceutical Inc. (2.74), greater than Seagen Inc. (2.67), greater than Alnylam Pharmaceuticals, Inc. (3.17), less than Halozyme Therapeutics, Inc. (6.64), less than X4 Pharmaceuticals, Inc. (3.71), less than PDS Biotechnology Corporation (4.56), greater than PTC Therapeutics, Inc. (2.03), greater than Reata Pharmaceuticals, Inc. (3.21), less than Intercept Pharmaceuticals, Inc. (4.22), less than Krystal Biotech, Inc. (12.66), less than Kodiak Sciences Inc. (10.12), less than Sarepta Therapeutics, Inc. (4.05), less than Mirati Therapeutics, Inc. (7.54),

Build a custom stock screener for Exelixis, Inc. (EXEL) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Exelixis, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Exelixis, Inc. (EXEL) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Exelixis, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.